[go: up one dir, main page]

MX2020007462A - Metodos de tratamiento de enfermedades inflamatorias cronicas. - Google Patents

Metodos de tratamiento de enfermedades inflamatorias cronicas.

Info

Publication number
MX2020007462A
MX2020007462A MX2020007462A MX2020007462A MX2020007462A MX 2020007462 A MX2020007462 A MX 2020007462A MX 2020007462 A MX2020007462 A MX 2020007462A MX 2020007462 A MX2020007462 A MX 2020007462A MX 2020007462 A MX2020007462 A MX 2020007462A
Authority
MX
Mexico
Prior art keywords
inflammatory diseases
chronic inflammatory
treating chronic
methods
calcium lactate
Prior art date
Application number
MX2020007462A
Other languages
English (en)
Inventor
Chong- Hwan Chang
Keun - Yeong JEONG
Original Assignee
Metimedi Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metimedi Pharmaceuticals Co Ltd filed Critical Metimedi Pharmaceuticals Co Ltd
Publication of MX2020007462A publication Critical patent/MX2020007462A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere al método de tratamiento de enfermedades inflamatorias crónicas en sujetos que lo necesitan mediante la administración de lactato de calcio como un agente activo; el lactato de calcio se puede proporcionar en una composición farmacéutica, alimenticia o nutritiva.
MX2020007462A 2018-01-12 2019-01-11 Metodos de tratamiento de enfermedades inflamatorias cronicas. MX2020007462A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862616923P 2018-01-12 2018-01-12
PCT/IB2019/050240 WO2019138379A1 (en) 2018-01-12 2019-01-11 Methods of treating chronic inflammatory diseases

Publications (1)

Publication Number Publication Date
MX2020007462A true MX2020007462A (es) 2020-09-14

Family

ID=67219526

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020007462A MX2020007462A (es) 2018-01-12 2019-01-11 Metodos de tratamiento de enfermedades inflamatorias cronicas.
MX2023005014A MX2023005014A (es) 2018-01-12 2020-07-13 Metodos de tratamiento de enfermedades inflamatorias cronicas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023005014A MX2023005014A (es) 2018-01-12 2020-07-13 Metodos de tratamiento de enfermedades inflamatorias cronicas.

Country Status (14)

Country Link
US (5) US10751365B2 (es)
EP (1) EP3737363A4 (es)
JP (2) JP7290870B2 (es)
KR (2) KR20200099172A (es)
CN (2) CN111587110A (es)
AU (2) AU2019206492B2 (es)
BR (1) BR112020013111A2 (es)
CA (1) CA3087953A1 (es)
EA (1) EA202091446A1 (es)
MX (2) MX2020007462A (es)
PH (1) PH12020551060A1 (es)
SG (1) SG11202006601VA (es)
TW (2) TW202416942A (es)
WO (1) WO2019138379A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019206492B2 (en) * 2018-01-12 2025-01-09 Metimedi Pharmaceuticals Co., Ltd. Methods of treating chronic inflammatory diseases
KR20230149007A (ko) * 2022-04-19 2023-10-26 (의) 삼성의료재단 생리활성물질 전달체
WO2025006927A1 (en) 2023-06-30 2025-01-02 Noxy Health Products, Inc. Nitric oxide containing foam formulation for topical medical use
EP4502147A1 (en) 2023-07-31 2025-02-05 M2Rlab SL Method for the polarization of cells to a new m2 phenotype and uses of said m2-polarized cells
CN118598194A (zh) * 2024-05-09 2024-09-06 川北医学院附属医院 一种钨基多金属氧酸盐的制备方法、钨基多金属氧酸盐及其应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3709989A (en) * 1970-09-14 1973-01-09 H Schneyer Composition and method for treatment of ossilets and pathological calcification in animals
US5908836A (en) 1987-12-21 1999-06-01 Bar-Shalom; Daniel Protecting skin from radiation damage using sulphated sugars
PL168049B1 (pl) * 1992-07-06 1995-12-30 Lodzkie Zaklady Farma Sposób wytwarzania preparatu o działaniu przeciwzapalnym
US5958436A (en) 1995-12-21 1999-09-28 Cosmederm Technologies Formulations and methods for reducing skin irritation
US20060165784A1 (en) * 1997-05-06 2006-07-27 Zhao Jin R Calcium supplement
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US20050245612A1 (en) 2004-05-03 2005-11-03 Blass John P Pharmaceutical compositions for metabolic insufficiencies
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6036985A (en) 1998-04-03 2000-03-14 Nestec S.A. Calcium complex and food fortified therewith
CN1068778C (zh) 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
US5980863A (en) 1998-11-02 1999-11-09 Eagle Vision Pharmaceutical Corporation Manganese compositions and methods for MRI
WO2000048573A1 (de) * 1999-02-19 2000-08-24 Bioserv Ag Bioabbaubare komposite zur herstellung von mikrokapseln
WO2000067750A1 (en) 1999-05-05 2000-11-16 Unilever N.V. Food product
US6261610B1 (en) 1999-09-24 2001-07-17 Nestec S.A. Calcium-magnesium fortified water, juices, beverages and other liquid food products and process of making
EP1129715A1 (de) 2000-02-25 2001-09-05 Werner Dr. Reichen Anwendung von Magnesium, Kalzium und Silizium zur Heilung verschiedener Krankheiten und zum allgemeinen Wohlbefinden
CA2410885C (en) 2000-06-02 2010-07-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases
US6687428B2 (en) 2000-09-21 2004-02-03 Tera Op (Usa) Inc. Optical switch
KR100911382B1 (ko) 2001-02-28 2009-08-07 에자끼구리고가부시키가이샤 항-충치 기능을 지닌 조성물
ITMI20011495A1 (it) 2001-07-12 2003-01-12 Pharmaproducts Uk Ltd Sali di calcio ad attivita' citotossica
DE10135493A1 (de) 2001-07-20 2003-01-30 Jobst Krauskopf Pharmazeutische Zusammensetzung zur Behandlung von Hypercholesterinämie
DE10135494A1 (de) * 2001-07-20 2003-11-06 Jobst Krauskopf Verwendung eines Lactatsalzes zur Behandlung und Prophylaxe der Athereosklerose
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
FR2834641B1 (fr) 2002-01-14 2005-04-22 Ct Regional De Lutte Contre Le Protection de la neurotoxicite de l'oxaliplatine par administration de calcium et de magnesium
HUP0200337A2 (hu) 2002-01-30 2005-09-28 Sanofi-Aventis Stabilizált provastatin-nátriumot tartalmazó gyógyászati készítmény
DE10233229A1 (de) * 2002-07-22 2004-02-12 S.K. Enterprise Gmbh Pharmazeutische Zusammensetzung zur Senkung des Triglyceridspiegels
US6946151B2 (en) 2002-11-12 2005-09-20 Ayurvedic-Life International, Llc Therapeutic compositions
WO2005000205A2 (en) 2003-06-02 2005-01-06 Samaritan Pharmaceuticals, Inc. Methods and compositions for modulating serum cortisol levels
US20040253323A1 (en) 2003-06-11 2004-12-16 Giles Brian C. Ionic cancer therapy and methods for using same in the treatment of tumors and metastasis
RU2235534C1 (ru) * 2003-10-28 2004-09-10 Киппер Светлана Николаевна Средство для полоскания рта
IL166114A0 (en) 2005-01-03 2006-01-15 Calcident Active Ltd Long-acting controlled-release pharmaceutical preparation for use in the oral cavity
US20070082027A1 (en) 2005-10-07 2007-04-12 Aimutis William R Jr Compositions and methods for reducing food intake and controlling weight
UA95093C2 (uk) 2005-12-07 2011-07-11 Нікомед Фарма Ас Спосіб одержання кальцієвмісної сполуки
WO2007114791A1 (en) 2006-04-03 2007-10-11 Innogene Kalbiotech Pte Ltd Lactate and calcium containing pharmaceutical composition and uses thereof
US20070292493A1 (en) 2006-06-15 2007-12-20 Brierre Barbara T Pharmaceutical composition and method for the transdermal delivery of calcium
US20100015068A1 (en) 2006-07-06 2010-01-21 Massachusetts Institute Of Technology Methods and Compositions For Altering Biological Surfaces
CN101134037A (zh) 2006-07-20 2008-03-05 杨喜鸿 利莫那班或其可药用盐的肠溶制剂及其制备方法
WO2008102214A2 (en) 2007-02-22 2008-08-28 Ghassemian Pour Bavandi, Madjid Endodontic filling material
US9295677B2 (en) 2008-02-26 2016-03-29 Qing Bile Therapeutics Inc. Polyhydroxylated bile acids for treatment of biliary disorders
MX2011009956A (es) * 2009-03-26 2012-01-27 Pulmatrix Inc Formulaciones de citrato de calcio y lactato de calcio para la modificacion de las propiedades biofisicas del revestimiento mucosal.
WO2010119424A2 (fr) 2009-04-15 2010-10-21 Exichol Sa Composition destinee a la regulation du metabolisme des lipides
EP3563842A1 (en) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AR076576A1 (es) 2009-05-13 2011-06-22 Wyeth Llc Procedimiento para estabilizar un suplemento dietetico para facilitar la salud de las articulaciones en seres humanos
CN102470237A (zh) 2009-06-26 2012-05-23 塔里斯生物医药公司 用于可植入药物递送装置的固体药物片剂
CN101584889B (zh) * 2009-07-10 2012-12-12 山东大学威海分校 一种用于治疗牙周病的外用原位成型基质
WO2011152810A1 (en) 2010-06-03 2011-12-08 Bilgic Mahmut Formulations comprising calcium, vitamin d and vitamin k for osteoporosis
CN102309456B (zh) 2010-07-02 2013-05-01 北京化工大学 一种厄贝沙坦纳微复合粉体与片剂及其制备方法
KR20120012119A (ko) * 2010-07-30 2012-02-09 주식회사 하이닉스반도체 레이턴시 제어 회로 및 그의 동작 방법
US8758824B2 (en) * 2010-08-30 2014-06-24 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
US20120064178A1 (en) 2010-09-13 2012-03-15 Carolyn Flora Anne Dean Cell-8 Solution
US9931365B2 (en) 2010-09-28 2018-04-03 Lisa Geng Methods for treating neurological disorders using nutrient compositions
EP2651415B1 (en) 2010-12-13 2020-10-07 Rite-Prep Pty Ltd. Gastric and colonic formulations and methods for making and using them
WO2012104654A1 (en) * 2011-02-04 2012-08-09 Biocopea Limited Compositions and methods for treating cardiovascular diseases
KR20180100455A (ko) 2011-04-13 2018-09-10 아지노모토 가부시키가이샤 영양 조성물
KR20120121196A (ko) * 2011-04-26 2012-11-05 주식회사 글루칸 관절염 치료제
EP2599477A1 (en) 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
JP2015518475A (ja) 2012-04-10 2015-07-02 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 非アルコール性脂肪性肝炎の治療方法
WO2013184943A1 (en) 2012-06-07 2013-12-12 Novabone Products, Llc Silica-coated calcium salt compositions
US20150366908A1 (en) 2012-06-07 2015-12-24 Novabone Products, Llc Silica-coated calcium salt compositions
CN103110133A (zh) 2012-11-15 2013-05-22 沈阳洪达信息科技有限公司 一种含有阿胶的火腿肠
EP2799060A1 (en) 2013-04-30 2014-11-05 Aprofol AG Stable high dose pharmaceutical composition comprising levoleucovorin
CN103230409B (zh) * 2013-05-10 2014-12-31 张晓春 一种治疗肠道疾病的药物及应用
CN103535580B (zh) 2013-10-22 2015-05-20 武汉哈福科技有限公司 一种补充多种微量元素的保健食品及其制备方法
CN103948915B (zh) 2014-05-05 2016-06-22 德立唯（北京）生物科技有限公司 一种能够提高稳定性和口服疗效的用于预防血栓形成和溶栓的纳豆激酶组合物
WO2016011335A1 (en) 2014-07-17 2016-01-21 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
CN105687173A (zh) * 2014-11-24 2016-06-22 光明乳业股份有限公司 乳酸和/或其盐在制备单胺氧化酶抑制剂中的用途
KR101683635B1 (ko) 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
US20160271085A1 (en) 2015-03-20 2016-09-22 Joel Steven Goldberg Treatment of amyotrophic lateral sclerosis with lactate
CN108348553A (zh) 2015-11-20 2018-07-31 雀巢产品技术援助有限公司 使用乳清蛋白以改善或维持肌肉质量的方法
JOP20170147B1 (ar) 2016-07-07 2021-08-17 Salvat Lab Sa تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة
KR20180062063A (ko) 2016-11-30 2018-06-08 (주) 메티메디제약 서방형 항암용 약학 조성물
AU2019206492B2 (en) * 2018-01-12 2025-01-09 Metimedi Pharmaceuticals Co., Ltd. Methods of treating chronic inflammatory diseases

Also Published As

Publication number Publication date
PH12020551060A1 (en) 2021-05-31
US20190247426A1 (en) 2019-08-15
KR20250042852A (ko) 2025-03-27
EP3737363A4 (en) 2021-10-20
JP7665220B2 (ja) 2025-04-21
EP3737363A1 (en) 2020-11-18
CN120241688A (zh) 2025-07-04
KR20200099172A (ko) 2020-08-21
WO2019138379A1 (en) 2019-07-18
AU2019206492B2 (en) 2025-01-09
BR112020013111A2 (pt) 2020-12-01
SG11202006601VA (en) 2020-08-28
TW201940180A (zh) 2019-10-16
MX2023005014A (es) 2023-05-16
US20200352988A1 (en) 2020-11-12
US20230302046A1 (en) 2023-09-28
CN111587110A (zh) 2020-08-25
US11684635B2 (en) 2023-06-27
US10751365B2 (en) 2020-08-25
US20240024356A1 (en) 2024-01-25
JP7290870B2 (ja) 2023-06-14
CA3087953A1 (en) 2019-07-18
US20210106614A1 (en) 2021-04-15
JP2023078291A (ja) 2023-06-06
JP2021510368A (ja) 2021-04-22
TWI827577B (zh) 2024-01-01
EA202091446A1 (ru) 2021-01-29
US10898514B2 (en) 2021-01-26
US12138281B2 (en) 2024-11-12
AU2019206492A1 (en) 2020-07-16
TW202416942A (zh) 2024-05-01
AU2024278252A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
MX2020007462A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
BR112018075998A2 (pt) composições antifúngicas sinérgicas e métodos das mesmas
EA201792547A1 (ru) Популяции бактерий для стимуляции состояния здоровья
AR106768A1 (es) Composiciones que comprenden cepas bacterianas
BR112018003212A2 (pt) diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3
AR093386A1 (es) Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento
BR112017006113A2 (pt) combinações sinérgicas de auristatina
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
MX388251B (es) Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo.
AR100618A1 (es) Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
TN2017000258A1 (en) Pyrazolopyridinamines as mknk1 and mknk2 inhibitors
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
AR095594A1 (es) Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos
CL2018001719A1 (es) Tratamiento contra el mieloma múltiple (divisional solicitud 201600396)
EA201992389A1 (ru) Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
EP3403656A4 (en) COMPOSITION FOR PREVENTING, HEALING OR TREATING THE FEMALE CLIMATE SYNDROME WITH LOGANINE OR DERIVATIVES THEREOF AS AN ACTIVE SUBSTANCE
EA201500752A1 (ru) Способ лечения заболеваний
BR112018000252A2 (pt) métodos e composições farmacêuticas para intensificar atividades de eliminação de célula nk
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MX2016002307A (es) Tratamiento para el cancer.